AI Summary

A large U.S. insurance‑claims analysis found that many patients with early‑stage breast cancer do not consistently maintain the long‑term hormone therapy prescribed after lumpectomy. The study highlights real‑world adherence challenges for patients expected to continue medication for at least five years. These findings provide context for treatment strategies that consider omitting radiation therapy, which rely on the assumption of sustained endocrine therapy adherence.

AI summaries can be wrong sometimes—always verify important details using the source article.